�鶹��ýӳ��

Educational Background

Dr. Han completed his Ph.D. through a joint training program between Shandong University and the University of Nebraska–Lincoln, followed by postdoctoral research at Cheeloo Medical School, Shandong University.

Professional Experience

Dr. Han has extensive experience in both academia and the pharmaceutical industry. He currently serves as an Assistant Professor in the Department of Biomedical Engineering at the �鶹��ýӳ��. Prior to joining �鶹��ýӳ��, he was a Research Assistant Professor at Ohio University. He also has several years of pharmaceutical industry experience in drug discovery, process development, scale-up, and manufacturing.

Current Courses

BIO 5515 Pharmacology & Drug Design

Selected Publications

• Carolina E. Portero, Shiyong Wu, M. Raquel Marchán-Rivadeneira, Yong Han*. Synthetic probiotic bacteria for in-situ production and delivery of bioactive compounds derived from nature. Journal of Biological Chemistry 2026, 302(5).
• Yuying Li, Zeran Bian, Yingsong Wang, Huihui Song, Xindong Li, Yuxiang Zhu, Jia Wang, Alexandria Montavon, Yong Han, Yan Wang. Bfcr, a novel global regulatory factor of marine Pseudomonas aeruginosa SM45 enhancing biofilm formation. Marine Life Science & Technology 2026, https://doi.org/10.1007/s42995-026-00357-6
• Carolina E. Portero, Claire Smith, Yuxi Zhou, M. Raquel Marchán-Rivadeneira, Shiyong Wu and Yong Han*. Construction of synthetic probiotic bacteria for in-situ delivery of anti-SARS-CoV-2-nanobodies. Probiotics and Antimicrobial Proteins 2025, https://doi.org/10.1007/s12602-025-10758-1
• Vishakha Jayasekera, Yong Han, Liangcheng Du. Identification of pyrrole-2-carboxylic acid from the biocontrol agent Lysobacter involved in interactions with Fusarial fungi. Microorganisms 2025, 13(6), 1202.
• Yuehan Yang, Mara Kessler, M. Raquel Marchán-Rivadeneira, Yuxi Zhou, Yong Han*. Adeno-Associated Virus mediated CRISPR-Cas13 knockdown of papain-like protease from SARS-CoV-2 virus. J-Multidisciplinary Scientific Journal 2024, 7(3), 393-405.
• Alexandria Montavon, M. Raquel Marchán-Rivadeneira, Yong Han*. Polycyclic tetramate macrolactams and their potential as anticancer agents. Organics 2024, 5, 361-377.  
• Haotong Chen, Yong Han, Abby Hearne, Anna Monarchino, Jeffrey S Wiseman. Purinergic ligands induce extracellular acidification and increased ATP turnover in HepG2 cells. Toxicology in Vitro 2024, 96, 105788.
• Haiyun Zhang, Jingwen Song, Ryan Ward, Yong Han, Arabella Hunt, Pratik Shriwas, Alexander Steed, Cory Edwards, Yanyang Cao, Milo Co, Xiaozhuo Chen. Diverse temporal and spatial mechanisms work, partially through Stanniocalcin-1, V-ATPase and senescence, to activate the extracellular ATP-mediated drug resistance in human cancer cells. Frontiers in Oncology 2024, 14, 1276092.
• Yuehan Yang, Mara Kessler, M. Raquel Marchán-Rivadeneira, Yong Han*. Combating Antimicrobial Resistance in the Post-Genomic Era: Rapid Antibiotic Discovery. Molecules 2023, 28 (10), 4183.
• Zhihong Chen, Xin Liu, Liwen Chen, Yong Han, Yuemao Shen, Bilian Chen, Mingzi Wang. Deglycosylation Inactivation Initiated by a Novel Periplasmic Dehydrogenase Complex Provides a Novel Strategy for Eliminating the Recalcitrant Antibiotic Kanamycin. Environmental Science & Technology 2023, 57(10), 4298-4307.
• Carolina E. Portero, Yong Han, M. Raquel Marchán-Rivadeneira. Advances on the biosynthesis of pyridine rings. Engineering Microbiology, 2023, 100064.
• Lingying Tong, Weichao Sun, Shiyong Wu and Yong Han*. Characterization of Caerulomycin A as a Dual-targeting Anticancer Agent. European Journal of Pharmacology 2022, 922: 174914.
• Yuxiang Zhu, Yong Han, Guang-Lei Liu, Zeran Bian, Xiayi Yan, Yaoyao Li, Hongan Long, Guanshuo Yu, Yan Wang. A novel indole-mediated potassium ion import system confers a competitive advantage to the Xanthomonadaceae family. ISME Journal 2022, 16, 1717–1729. (co-first author)
• Yuxi Zhou, Yong Han*. Engineered Bacteria as Drug Delivery Vehicles: Principles and Prospects. Engineering Microbiology 2022, 100034.
• Cuilin Cheng, Haotong Chen, Lingying Tong, Shiyong Wu and Yong Han*. Mathermycin, an anti-cancer molecule that targets cell surface phospholipids. Toxicol Appl Pharm. 2021, 413: 115410.
• Yong Han*, Yan Wang, Yuehan Yang and Haotong Chen. Shellmycin A-D, Novel Bioactive Tetrahydroanthra-γ-pyrone Antibiotics from Marine Streptomyces sp. shell-016. Marine Drugs 2020; 18(1): 58. (corresponding author)
• Tao Feng, Yong Han, Bingqing Li, Zhiqiang Li, Yameng Yu, Qingyang Sun, Xiaoyu Li, Liangcheng Du, Xiao-Hua Zhang, and Yan Wang. Interspecies and Intraspecies Signals Synergistically Regulate the Twitching Motility of Lysobacter enzymogenes. Applied and Environmental Microbiology. 2019;85: 23. doi: 10.1128/aem.01742-19. (co-first author)
• Haotong Chen, Yong Han, Ishrat Jahan, Shiyong Wu, Brian C Clark, Jeffrey S Wiseman. Extracts of maca (Lepidium meyenii) root induce increased glucose uptake by inhibiting mitochondrial function in an adipocyte cell line. Journal of Herbal Medicine. 2019, 17:100282.
• Yan Wang, Tao Feng, Hui Li, Yameng Yu, Yong Han, Jingjing Zhang, Xiaoyu Li, Yaoyao Li, Xiao-Hua Zhang. A novel heterologous expression strategy for the quorum-quenching enzyme MomL in Lysobacter enzymogenes to the inhibit pathogenicity of Pectobacterium. Applied microbiology and biotechnology. 2019,103: 8889-8898.
• Yong Han, Yan Wang, Yameng Yu, Haotong Chen, Yuemao Shen and Liangcheng Du. Indole-induced reversion of intrinsic multi-antibiotic resistance in Lysobacter enzymogene. Applied and Environmental Microbiology.  2017, doi:  10.1128/AEM.00995-17.
• Zhenhe Su, Hongfu Chen, Ping Wang, Simon Tombosa, Liangcheng Du, Yong Han, Yuemao Shen, Guoliang Qian and Fengquan Liu. 4‐Hydroxybenzoic acid is a diffusible factor that connects metabolic shikimate pathway to the biosynthesis of a unique antifungal metabolite in Lysobacter enzymogenes. Molecular Microbiology. 2017, 104(1): 163–178.
• Yong Han, Yan Wang, Simon Tombosa, Stephen Wright, Justin Huffman, Yuemao Shen and Liangcheng Du. Identification of a small molecule signaling factor that regulates the biosynthesis of the antifungal polycyclic tetramate macrolactam HSAF in Lysobacter   enzymogenes.  Applied Microbiology and Biotechnology. 2015; 99: 801-811.
• Yong Han, Yaoyao Li, Yan Shen, Jie Li, Wenjun Li and Yuemao Shen. Oxoprothracarcin, a novel pyrrolo[1,4]benzodiazepine antibiotic from marine Streptomyces sp. M10946. Drug Discovery and Therapy 2013; 7(6):243-247.

Patent:

• Yong Han, Shiyong Wu. PROTACs targeting viral enzymes for precise treatment of COVID-19.  US20260166160.

Research

Dr. Han’s research focuses on integrating pharmaceutical sciences, natural products chemistry, synthetic biology, and bioengineering to discover and develop innovative therapeutics and novel treatment strategies. His research interests include the discovery and biosynthesis of bioactive natural products, microbe-host interactions, engineered microbial therapeutics, synthetic biology-based genetic circuit design, and living implantable biomaterials. His research is supported by the National Institutes of Health (NIH). His long-term goal is to translate fundamental research discoveries into clinically relevant therapeutic strategies for the prevention and treatment of cancer, metabolic diseases, antimicrobial-resistant infections, aging, and other human diseases.